Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Payers' Guide
FDA Approvals
,
Drug Updates
,
Payers' Guide
The Year 2015 Had Highest Number of Drug Approvals in the New Millennium, but with Controversy
Gary M. Owens, MD
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
FDA Approvals of Brand-Name Prescription Drugs in 2015
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Welcome to the Seventh Annual Payers' Guide to New FDA Approvals
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia
Lisa A. Raedler, PhD, RPh
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure
Loretta Fala
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals
Caroline Helwick
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure
Loretta Fala
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
6
7
8
9
10
11
12
Page 9 of 19
Results 81 - 90 of 185